Investor Relations

Recent Event

2024 Annual Meeting of Stockholders

Company Overview

 BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Investor Contact Information


BiomX, Inc.
22 Einstein St.
Floor 5
Ness Ziona 7414003

Investor Relations

Assaf Oron
Chief Business Officer

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.